Categories AlphaGraphs, Earnings, Health Care
A visual representation of Johnson & Johnson (JNJ) Q1 2020 earnings results
Johnson & Johnson (NYSE: JNJ) reported that its first-quarter 2020 earnings and revenue came in above the analysts’ expectations citing product sales as well as lower costs and expenses. Region-wise, sales were better in the US than international. The Consumer and Pharmaceutical segments experienced solid high-single-digit growths despite declines in the Medical Devices segment.
The company is mobilizing its resources in the fight against the COVID-19 pandemic. The impact of COVID-19 has been included in the guidance. The reported sales outlook for fiscal 2020 was lowered to $77.5-80.5 billion from $85.4-86.2 billion. Adjusted earnings guidance was reduced to $7.50-7.90 from $8.95-9.10.
Past Performance
4Q19 
3Q19 
2Q19
Most Popular
CVX Earnings: Chevron reports lower revenue and profit for Q3 2024
Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to
Key highlights from Exxon Mobil Corporation’s (XOM) Q3 2024 earnings results
Exxon Mobil Corporation (NYSE: XOM) reported its third quarter 2024 earnings results today. Total revenues and other income remained relatively flat at $90 billion compared to the same period a
AAPL Earnings: Apple Q4 2024 sales rise 6% YoY, beat estimates
Apple Inc. (NASDAQ: AAPL) reported an increase in revenues for the fourth quarter of 2024. The top line came in above estimates. The gadget giant generated revenues of $94.9 billion
Comments